Compare Devyser Diagnostics AB with Similar Stocks
Dashboard
1
The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at SEK 31.7 MM
- PRE-TAX PROFIT(Q) At SEK 4.4 MM has Grown at 751.85%
- NET PROFIT(Q) At SEK 2.9 MM has Grown at 238.1%
2
With ROE of -2.37%, it has a risky valuation with a 3.74 Price to Book Value
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,625 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.17
4.19%
4.54
Revenue and Profits:
Net Sales:
62 Million
(Quarterly Results - Mar 2026)
Net Profit:
3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.18%
0%
11.18%
6 Months
-23.99%
0%
-23.99%
1 Year
-25.56%
0%
-25.56%
2 Years
-23.79%
0%
-23.79%
3 Years
10.05%
0%
10.05%
4 Years
23.57%
0%
23.57%
5 Years
0%
0%
0.0%
Devyser Diagnostics AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
27.99%
EBIT Growth (5y)
25.65%
EBIT to Interest (avg)
-31.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.59
Tax Ratio
3.56%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.74
EV to EBIT
116.90
EV to EBITDA
35.87
EV to Capital Employed
4.34
EV to Sales
5.04
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.71%
ROE (Latest)
-2.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
61.80
72.00
-14.17%
Operating Profit (PBDIT) excl Other Income
10.30
25.20
-59.13%
Interest
0.70
2.10
-66.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.90
13.60
-78.68%
Operating Profit Margin (Excl OI)
45.30%
252.80%
-20.75%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -14.17% vs 27.66% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -78.68% vs 585.71% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
250.50
216.90
15.49%
Operating Profit (PBDIT) excl Other Income
32.00
-40.60
178.82%
Interest
3.00
3.50
-14.29%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-8.40
-61.50
86.34%
Operating Profit Margin (Excl OI)
42.30%
-292.80%
33.51%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 15.49% vs 28.12% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 86.34% vs -14.74% in Dec 2024
About Devyser Diagnostics AB 
Devyser Diagnostics AB
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






